Office Address:
Atul Aggarwal MD Cardiology Clinic
9330 Stockdale Hwy Suite 200
Bakersfield, California 93311
Phone: 661.664.0100
Hospital Appointments:
• Bakersfield Heart Hospital
• Bakersfield Memorial Hospital
• Mercy Hospital, Bakersfield
• Mercy Southwest Hospital, Bakersfield
• San Joaquin Community Hospital, Bakersfield

 

Current Status:
Interventional Cardiologist, Atul Aggarwal MD Cardiology Clinic
Perform all aspects of exercise and pharmacological stress testing, transthoracic and transesophageal echocardiography, peripheral vascular non-invasive imaging, stress testing and myocardial perfusion imaging, coronary computed cardiovascular tomographic angiography, cardiac catheterization, and complex percutaneous coronary interventions including balloon angioplasty, intracoronary stenting, rotational atherectomy, and intracoronary ultrasound.
First cardiologist performing transeptal atrial septal occluder implantations in Kern County, CA
Credentials to perform peripheral vascular interventions (renal and iliofemoral interventions).
Have performed more than 1600 percutaneous coronary interventions, 3000 left heart catheterizations, and interpreted 7500 transthoracic echocardiograms, 450 transesophageal echocardiograms, 56 stress echocardiograms, 13,500 nuclear SPECT imaging scans, and actively interpret Cardiovascular/Coronary Computed Tomographic angiograms (CTCA)
Academic Appointments:
Assistant Instructor in Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India, 1/92 – 12/94
Assistant Instructor in Internal Medicine, State University of New York, Syracuse, NY, 7/96 – 6/99
Instructor in Internal Medicine, Fletcher Allen Health Care, University of Vermont, 7/99 – 6/03
Assistant Clinical Professor, Department of Medicine, University of California at Los Angeles, 7/09 – present
Licensure:
Punjab Medical Council (India), 1991
Vermont State Licensure, 1999
Nebraska State License, 2003
California State Medical License, 2008
Michigan State License, 2006
Ohio State License, 2008
Pennsylvania State License, 2008
Certifications:
American Board of Internal Medicine, 1999
Board Certification in Cardiovascular Disease, 2002
American Society of Nuclear Cardiology, 2001
Board Certification in Interventional Cardiology, 2003
Education:
1986-1991
M.B.B.S.
Dayanand Medical College and Hospital
Ludhiana, India
1984-1986
B.S.
SCD Government College
Ludhiana, India
Postgraduate Education:
Residency:
January 1992 – December 1994
Internal Medicine Residency
Dayanand Medical College and Hospital
Ludhiana, India
July 1996 – June 1999
Internal Medicine Residency
State University of New York (Upstate University)
Syracuse, NY
Fellowships:
July 1999 – June 2002
Adult cardiology Fellowship
Fletcher Allen Health Care
University of Vermont, Burlington
July 2002 – June 2003
Interventional Cardiology Fellowship
Fletcher Allen Health Care
University of Vermont, Burlington
Awards:
Gold Medal for Residency in Internal Medicine, 1994
Distinctions in Medical School in Subjects of Anatomy, Pathology, Microbiology, Pharmacology, 1986-90
Gold Medals in Subjects of Internal Medicine, Surgery, Obstetrics and Gynecology, 1986-90
Silver Medal in Social and Preventive Medicine, 1986-90
Silver Medal in Final Year of Medical School, 1990
Third in Panjab University, Chandigarh, India (Premedical-BSc Class 1986)
Professional Affiliations:
American Medical Association, 1996
American College of Chest Physicians (honorary member), 2000
American College of Cardiology (Fellow), 2005
Society of Cardiovascular Angiography and Interventions (Fellow), 2006
Indo-American Society of Interventional Cardiologists, 2005
American Heart Association (Fellow) – Council on clinical cardiology, 2007
Society of Computed Cardiovascular Tomography, 2007
Publications:
Aggarwal A, Chopra SC, Wander GS, Khurana SB. Antihypertensive response to sublingual drug as a guide to predict its long-term effectiveness: A study with nifedipine and captopril. (Dissertation for residency in Internal Medicine) 1994
Aggarwal A. Amiodarone to prevent recurrence of atrial fibrillation (Correspondence). N Engl J Med 2000;343(8):578-9
Aggarwal A. Prevention of sudden death in patients with coronary artery disease (Correspondence). N Engl J Med 2000;342(17):1291
Aggarwal A, Brown KA, and LeWinter MM. Diastolic Dysfunction: Pathophysiology, clinical features and diagnosis using radionuclide methods. J Nucl Cardiol 2001;8:98-106
Aggarwal A, Ades PA. Exercise rehabilitation in elderly patients with cardiac disease. Cardiology Clinics 2001;19:525-536
Aggarwal A, Ades PA. Interactions of herbal remedies with prescription cardiovascular medications. Coronary Artery Disease 2001;12:1-4
Jaffery J, Aggarwal A, Ades PA, Weise WJ. A long sweet sleep with sour consequences (Case report). Lancet 2001;358:1236
Kabbani SS, Aggarwal A, Terrien ET, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban: Implications for coronary interventions. American Journal of Cardiology 2002;89:547-600
Aggarwal A, Battle RW. Congenital absence of the left pericardium (Clinical picture). Lancet 2002;360:2038
Aggarwal A, Klein JS, Battle RW. A 59-year-old asymptomatic man with systolic murmur and mediastinal mass (Roentgenogram of the month). Chest 2003;123:1289-1292
Aggarwal A. I wonder what could have been (Code blue stories). Hosp Physician 1999;35(3):16 (web archive at http://www.turnerwhite.com/memberfile.php?PubCode=hp_mar99_cbwonder.pdf)
Aggarwal A, Leavitt BJ. Giant Lambl?s Excrescence (Images in Clinical Medicine). New England Journal of Medicine 2003;349:e24
Aggarwal A, Kabbani SS, Rimmer JM, Gennari JF, Taatjes DJ, Sobel BE, Schneider DJ. Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease, a potential contributor to cardiovascular risk. American Journal of Kidney Disease 2002;40(2):315-22
Schneider DJ, Lakkis N, Aguirre F, Aggarwal A, Kabbani SS, DiBattiste PM, Herrmann HC. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. American Journal of Cardiology 2002;90(12):1421-23
Aggarwal A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: Implications for coronary intervention. Journal of Thrombosis and Thrombolysis 2002;13(3);161-165
Tischler MD, Aggarwal A. Management of mitral regurgitation due to mitral prolapse. Current Treatment Options in Cardiovascular Medicine 2002;4:521-527
Aggarwal A, Terrien EF, Terrien CM. Treatment of totally occluded saphenous vein grafts using self-expanding stents. Coronary Artery Disease 2002;13(7):373-6
Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo M, Aggarwal A, Kabbani SS, DiBattiste PM. Increased concentrations of tirofiban and their correlation with the inhibition of platelet aggregation with greater bolus doses of tirofiban. American Journal of Cardiology 2003;91:334-6
Aggarwal A, Schneider DJ, Terrien EF, Terrien CM, Sobel BE, Dauerman HL. Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interlukin-6, and interleukin- receptor antagonist after coronary arterial stenting. American Journal of Cardiology 2003 Jun 1;91(11):1346-9.
Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. American Journal of Cardiology 2003;92:924-9
Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD 40 ligand indicative of inflammation associated with culprit coronary atherosclerotic plaques. American Journal of Cardiology 2004 Jan 1;93(1):6-9
Aggarwal A. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction (Correspondence). N Engl J Med 2003;349:88
Aggarwal A, Schneider DJ, Terrien EF, Gilbert K, Dauerman HL. Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory response. Journal of Thrombosis and Thrombolysis 2003;15(1):25-31
Aggarwal A, Whitaker DA, Rimmer JM, Solomon RJ, Gennari FJ, Sobel BE, Schneider DJ. Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing hemodialysis. Nephrology Dialysis and Transplantation 2004;19:1559-63. Epub 2004 Mar 19
Gutierrez MJ, Aggarwal A, Gilbert K, Sobel BE, Dauerman HL. Use of femoral closure devices as part of a pharmacoinvasive reperfusion strategy. Journal of Thrombosis and Thrombolysis 2004 Dec;18 (3):187-92.
Aggarwal A, Blum A, Schneider DJ, Sobel BE, Dauerman HL. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coronary Artery Disease 2004 Dec;15(8):471-5
Schneider DJ, Aggarwal A. Development of glycoprotein IIb-IIIa antagonists: translation of pharmacodynamic effects into clinical benefit. Expert Review of Cardiovascular Therapy 2004 Nov;2(6):903-13.
Aggarwal A. The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Correspondence. American Heart Journal 2006 May;151(5):e2
Aggarwal A. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Correspondence. American Heart Journal 2006 May;151(5):e3
Aggarwal A. Inflammatory response to drug eluting stent placement. Correspondence. Am J Cardiol 2006;98 (9):1299
Aggarwal A, Dai D, Rumsfeld JS, Klein LW, Roe MT. Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention. American Journal of Cardiology 2008;101:1413-1417.
Aggarwal A, Dai D, Rumsfeld JS, Klein LW, Roe MT on behalf of American College of Cardiology National Cardiovascular Data Registry. Incidence and predictors of stroke associated with percutaneous coronary intervention. American Journal of Cardiology 2009;104:349-353
Aggarwal A, Wang Y, Rumsfeld JS, Curtis JP, Heidenreich PA; National Cardiovascular Data Registry. Clinical Characteristics and In-Hospital Outcome of Patients with End Stage Renal Disease on Dialysis Referred for Implantable Cardioverter Defibrillator Implantation. Heart Rhythm 2009;6(11):1565-71. Epub 2009 Aug 5
Aggarwal A, Ou FS, Rumsfeld JS, Klein LW, Roe MT, Wang TY, on behalf of American College of Cardiology National Cardiovascular Data Registry. Incidence, Predictors and In-hospital Outcomes of No Reflow Phenomenon during Percutaneous Coronary Intervention for Acute Myocardial Infarction. Submitted.
Reviews:
Lancet 2001 (1)
Circulation 2009 (1)
Coronary Artery Disease 2001 (1), 2002 (7), 2003 (5), 2004 (4), 2005 (5), 2006 (3), 2007 (7), 2008 (6), 2009 (6), 2010 (3)
Chest 2002 (3), 2004 (1),
Atherosclerosis 2004 (1),
American Journal of Kidney Dis 2003 (3), 2008 (1), 2009 (2), 2010 (3)
American Journal of Cardiology 2005 (4), 2006 (5), 2007 (6), 2008 (5), 2009 (5)
Nephrology Dialysis Transplantation 2005 (1), 2006 (1), 2007 (1), 2008 (1)
Blood, Coagulation and Fibrinolysis 2005 (1)
Pathophysiology of Haemostasis and Thrombosis 2005 (1)
Acta Clinica Chimica 2006 (3)
Life Sciences (2)
EDITORIAL BOARD – 1. Coronary Artery Disease (Editor – Burton E. Sobel, MD, Lippincott)
                                  2. Cardiology Research and Practice (SAGE publications)
Abstract grader for American Heart Association Scientific Sessions 2008, 2009, 2010 (Clinical Cardiology, Genetics and Proteonomics)
Speakers Bureau
The Medicines Company, Sanofi/Bristol Myers Squibb partnership
Research Clinical Trial Participation:
Principal site investigator for SOLID TIMI 52 (The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial). Enrollment open
Principal site investigator for SAVOR TIMI 53 (Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications). Enrollment open
Prinicipal site investigator for TIMI-2P50. Patients enrolled = 7 (enrollment closed)
Prinicipal site investigator for EARLY ACS (The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome Trial). (Patients enrolled = 3, enrollment closed).
Prinicipal site investigator for IMPROVE IT [Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs. Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial]. (Patients enrolled =11, enrollment closed)
Prinicipal site investigator for TRA-PCI (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Thrombin Receptor Antagonist in PCI). (Patients enrolled =5, enrollment closed)
Principal site investigator for TENACITY (Tirofiban Evaluation of Novel Dosing vs. Abciximab with Clopidogrel and Inhibition of Thrombin Study), a multicenter study evaluating higher bolus dose of tirofiban in combination with optimal antithrombotic therapy for patients undergoing urgent percutaneous coronary intervention. 2005 (enrollment closed; Patients enrolled = 14)
Principle site investigator for ARISTOTLE (A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixiban in Preventing Stroke and Systemic Embolism on Subjects with Nonvalvular Atrial Fibrillation. (Enrollment open; patients enrolled =8)
Principle site investigator for PLATO (Enrollment closed; patients enrolled =1)
Sub-Investigator for DRIVER REGISTRY. Post release registry to assess acute procedural success with the Driver coronary stent (Sponsor ? Medtronic, Inc) 10/04-present.
Sub-investigator for TAXUS V ISR (A prospective, randomized trial evaluating the slow-release formulation TAXUS?Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis (enrollment closed)
Sub-investigator for Apex AMI (A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (enrollment closed). Sponsor ?Alexion and P&G Pharmaceuticals.
Sub-investigator for Endeavour IV Trial (A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System versus the TAXUS Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Lesions). (enrollment closed 04/05 to present). Sponsor ? Medtronic
Sub-investigator for STRADIVARIUS (sanofi aventis EFC5827): A randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg for inhibition of atherosclerosis progression assessed by IVUS in overweight patients with clustering risk factors. (enrollment closed)
Sub-investigator for SPIRIT IV (Clinical Evaluation of the XIENCE? V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Coronary Artery Lesions) enrollment open
Sub-investigator for PERSUS-WH. Sponsor Boston Scientific
Abstracts:
Aggarwal A. Antihypertensive response to sublingual captopril predicts response to oral captopril (abstract). J Gen Intern Med 1999;14 (Suppl 2):5
Kabbani SS, Aggarwal A, Terrien ET, Stewart RE, Sobel BE, Schneider DJ. Inadequate early inhibition with tirofiban in conventional doses: A potential determinant of suboptimal effects after percutaneous coronary intervention (abstract). Circulation 2001;104:II-706
Aggarwal A, Schneider DJ, Terrien EF, Dauerman HL. Increased sensitivity of interleukin 6 to inflammatory changes after coronary stenting (abstract). Am J Cardiol 2002;90 (6A):118 H ? presented at Transcutaneous Catheter Therapeutics meeting, Washington, DC, September 2002
Aggarwal A, Schneider DJ, Terrien EF, Whitaker DA, Sobel BE, Dauerman HL. Increased concentration of interleukin-1 receptor antagonist associated with diabetes mellitus and in the vicinity of coronary plaques: a sensitive marker of inflammation (abstract). J Am Coll Cardiol 2003;41(6):285A ? presented at American College of Cardiology Annual Scientific Sessions, Chicago, Ill 2003
Aggarwal A, Schneider DJ, Terrien EF, Terrien CM, Watkins MW, Kabbani SS, Dauerman HL. Enhanced suppression of inflammation after coronary stenting (ESIS): A randomized clinical trial comparing abciximab and eptifibatide (abstract). J Am Coll Cardiol 2003;41(6):65A – presented at American College of Cardiology Annual Scientific Sessions, Chicago, Ill 2003
Aggarwal A, Schneider DJ, Terrien EF, O?Connell M, Sobel BE, Dauerman HL. A randomized comparison of effects of eptifibatide and abciximab on release of soluble CD 40 ligand after coronary stenting (abstract). Am J Cardiol 2003;92(6A):135L ? presented at Transcutaneous Catheter Therapeutics meeting, Washington, DC, September 2003
Gutierrez MJ, Aggarwal A, Borden F, Dauerman HL. Outcomes after femoral arteriotomy closure in patients undergoing percutaneous coronary intervention in the setting of thrombolytic therapy (abstract). Am J Cardiol 2003;92(6A):150L ? presented at Transcutaneous Catheter Therapeutics meeting, Washington, DC, September 2003
Aggarwal A, Rimmer JM, Solomon RJ, Gennari FJ, Sobel BE, Schneider DJ. Augmentation of platelet reactivity by unfractionated heparin compared with enoxaparin in patients undergoing hemodialysis (abstract). Presented at American Society of Nephrology Annual Scientific Sessions 2003, San Diego, CA
Dauerman HL, Aggarwal A, Sobel BE, Schneider DJ. A systemic inflammatory response reflected by increased soluble CD40 ligand is evident within 10 minutes of coronary stenting (abstract). J Am Coll Cardiol 2004;43(5):101A. Presented at American College of Cardiology Annual Scientific Sessions, New Orleans, LA 2004
Aggarwal A, Dai D, Rumsfeld JS, Klein LW, Roe MT, on behalf of American College of Cardiology National Cardiovascular Data Registry. Characteristics and outcomes of patients taking warfarin prior to percutaneous coronary intervention. Presented at American Heart Association 2007 Annual Scientific sessions, Orlando, FL. Circulation 2007;116:II-702
Aggarwal A, Dai D, Rumsfeld JS, Klein LW, Roe MT on behalf of American College of Cardiology National Cardiovascular Data Registry. Incidence and Predictors of stroke following percutaneous coronary intervention. Circulation 2008;118:S652 (presented as oral abstract for American Heart Association Annual Scientific Sessions 2008)
Aggarwal A, Wang Y, Rumsfeld JS, Curtis JP, Heidenreich PA, on behalf of American College of Cardiology National Cardiovascular Data Registry. Clinical Characteristics and In-Hospital Outcome of Patients with End Stage Renal Disease on Dialysis Referred for Implantable Cardioverter Defibrillator Implantation. Presented at American College of Cardiology Annual Scientific Sessions 2009, Orlando, FL. J Am Coll Cardiol 2009;53(10):A131
Aggarwal A, Ou FS, Rumsfeld JS, Klein LW, Roe MT, Wang TY, on behalf of American College of Cardiology National Cardiovascular Data Registry. Incidence, Predictors and In-hospital Outcomes of No Reflow Phenomenon during Percutaneous Coronary Intervention for Acute Myocardial Infarction. Circulation 2009;53(10):131A. Presented at American Heart Association Annual Scientific Sessions 2009, Orlando, FL.